NEW YORK (GenomeWeb News) – Drug developer Covance and Rules-Based Medicine have struck a biomarker alliance and services agreement, Covance said today.

Under the pact, RBM will serve as Covance's exclusive third-party provider of multiplexed biomarker testing services, and Covance will serve as RBM's exclusive referral source for lab testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.